The AIDS Healthcare Foundation on Monday filed a complaint in South Africa against drugmaker GlaxoSmithKline, claiming that the company's high drug prices block access to HIV antiretroviral treatments. The complaint was filed with the country's Competition Commission, an independent body that monitors fair market competition. Musa Ntsibande, the attorney representing the foundation in South Africa, said the complaint alleges that Glaxo "abused its dominant market position in contravention" of the country's Competition Act and engages in "excessive pricing of its drugs to the detriment of the consumer." The complaint calls for Glaxo to allow generic licensing and manufacturing concessions for some of its anti-HIV drugs, including AZT, 3TC, Ziagen, Combivir, and Trizivir. The commission has not yet responded to the complaint.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














